(ELV) Elevance Health - Ratings and Ratios
Health Plans, Pharmacy Services, Specialty Insurance, Care Management
ELV EPS (Earnings per Share)
ELV Revenue
Description: ELV Elevance Health September 26, 2025
Elevance Health, Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a broad portfolio of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and supplemental products such as dental, vision, and stop-loss insurance, while also operating a full-service pharmacy business that includes home delivery, specialty pharmacy, formulary management, and infusion services. Through its HealthOS platform, Elevance provides data-driven care-management tools, behavioral health, virtual care, payment-integrity solutions, and post-acute services, all under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands.
Key recent metrics underline the company’s scale and growth trajectory: FY 2023 revenue reached approximately $152 billion, with a medical loss ratio (MLR) of 86.5%-a benchmark for cost efficiency in managed care. Enrollment in Medicare Advantage grew 9% YoY, reflecting the aging U.S. population, while the pharmacy segment saw a 5% increase in specialty drug spend, driven by rising prevalence of chronic conditions. Sector-wide, inflationary pressure on medical services and ongoing regulatory reforms (e.g., ACA adjustments and Medicaid expansion in several states) are primary drivers of both premium growth and cost-containment initiatives.
For a deeper, data-rich analysis of Elevance Health’s valuation and risk profile, you may find ValueRay’s platform useful as a next step in your research.
ELV Stock Overview
| Market Cap in USD | 70,494m |
| Sub-Industry | Managed Health Care |
| IPO / Inception | 2001-01-02 |
ELV Stock Ratings
| Growth Rating | -48.9% |
| Fundamental | 69.9% |
| Dividend Rating | 70.4% |
| Return 12m vs S&P 500 | -34.8% |
| Analyst Rating | 4.41 of 5 |
ELV Dividends
| Dividend Yield 12m | 2.13% |
| Yield on Cost 5y | 2.24% |
| Annual Growth 5y | 14.45% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.0% |
ELV Growth Ratios
| Growth Correlation 3m | 75.6% |
| Growth Correlation 12m | -65.4% |
| Growth Correlation 5y | 20.1% |
| CAGR 5y | -14.02% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.28 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.82 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | -34.73 |
| Beta | 0.590 |
| Volatility | 28.04% |
| Current Volume | 1299.9k |
| Average Volume 20d | 1573.2k |
| Stop Loss | 306.6 (-3.6%) |
| Signal | 0.39 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (5.53b TTM) > 0 and > 6% of Revenue (6% = 11.69b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.75% (prev 7.58%; Δ 4.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 4.91b <= Net Income 5.53b (YES >=105%, WARN >=100%) |
| Net Debt (-7.78b) to EBITDA (10.02b) ratio: -0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.13% (target <= -2.0% for YES) |
| Gross Margin 50.46% (prev 27.94%; Δ 22.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 162.8% (prev 149.3%; Δ 13.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.16 (EBITDA TTM 10.02b / Interest Expense TTM 1.38b) >= 6 (WARN >= 3) |
Altman Z'' 3.11
| (A) 0.19 = (Total Current Assets 63.78b - Total Current Liabilities 40.88b) / Total Assets 122.75b |
| (B) 0.29 = Retained Earnings (Balance) 35.59b / Total Assets 122.75b |
| (C) 0.07 = EBIT TTM 8.48b / Avg Total Assets 119.64b |
| (D) 0.45 = Book Value of Equity 35.05b / Total Liabilities 78.67b |
| Total Rating: 3.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.88
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.01% = 3.00 |
| 3. FCF Margin 1.93% = 0.48 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -0.78 = 2.50 |
| 6. ROIC - WACC (= 1.31)% = 1.63 |
| 7. RoE 12.91% = 1.08 |
| 8. Rev. Trend 92.62% = 6.95 |
| 9. EPS Trend -5.23% = -0.26 |
What is the price of ELV shares?
Over the past week, the price has changed by -5.43%, over one month by -9.10%, over three months by +15.70% and over the past year by -22.47%.
Is Elevance Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELV is around 277.43 USD . This means that ELV is currently overvalued and has a potential downside of -12.78%.
Is ELV a buy, sell or hold?
- Strong Buy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 389.2 | 22.3% |
| Analysts Target Price | 389.2 | 22.3% |
| ValueRay Target Price | 309.3 | -2.8% |
ELV Fundamental Data Overview November 04, 2025
P/E Trailing = 12.9206
P/E Forward = 10.9529
P/S = 0.3618
P/B = 1.7523
P/EG = 0.8759
Beta = 0.59
Revenue TTM = 194.82b USD
EBIT TTM = 8.48b USD
EBITDA TTM = 10.02b USD
Long Term Debt = 29.22b USD (from longTermDebt, last fiscal year)
Short Term Debt = 929.0m USD (from shortTermDebt, last quarter)
Debt = 929.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.78b USD (from netDebt column, last quarter)
Enterprise Value = 62.71b USD (70.49b + Debt 929.0m - CCE 8.71b)
Interest Coverage Ratio = 6.16 (Ebit TTM 8.48b / Interest Expense TTM 1.38b)
FCF Yield = 6.01% (FCF TTM 3.77b / Enterprise Value 62.71b)
FCF Margin = 1.93% (FCF TTM 3.77b / Revenue TTM 194.82b)
Net Margin = 2.84% (Net Income TTM 5.53b / Revenue TTM 194.82b)
Gross Margin = 50.46% ((Revenue TTM 194.82b - Cost of Revenue TTM 96.51b) / Revenue TTM)
Gross Margin QoQ = 14.18% (prev 15.62%)
Tobins Q-Ratio = 0.51 (Enterprise Value 62.71b / Total Assets 122.75b)
Interest Expense / Debt = 37.78% (Interest Expense 351.0m / Debt 929.0m)
Taxrate = 15.58% (219.0m / 1.41b)
NOPAT = 7.16b (EBIT 8.48b * (1 - 15.58%))
Current Ratio = 1.56 (Total Current Assets 63.78b / Total Current Liabilities 40.88b)
Debt / Equity = 0.02 (Debt 929.0m / totalStockholderEquity, last quarter 43.95b)
Debt / EBITDA = -0.78 (Net Debt -7.78b / EBITDA 10.02b)
Debt / FCF = -2.07 (Net Debt -7.78b / FCF TTM 3.77b)
Total Stockholder Equity = 42.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 5.53b / Total Assets 122.75b)
RoE = 12.91% (Net Income TTM 5.53b / Total Stockholder Equity 42.87b)
RoCE = 11.76% (EBIT 8.48b / Capital Employed (Equity 42.87b + L.T.Debt 29.22b))
RoIC = 9.81% (NOPAT 7.16b / Invested Capital 72.99b)
WACC = 8.50% (E(70.49b)/V(71.42b) * Re(8.19%) + D(929.0m)/V(71.42b) * Rd(37.78%) * (1-Tc(0.16)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 77.39% ; FCFE base≈2.61b ; Y1≈2.54b ; Y5≈2.57b
Fair Price DCF = 199.8 (DCF Value 44.41b / Shares Outstanding 222.2m; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: -5.23 | EPS CAGR: 5.31% | SUE: 1.73 | # QB: 1
Revenue Correlation: 92.62 | Revenue CAGR: 10.03% | SUE: 1.33 | # QB: 5
Additional Sources for ELV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle